These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 26133776)

  • 1. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter.
    Apellániz-Ruiz M; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Sereno M; García-Donás J; Åvall-Lundqvist E; Gréen H; Brøsen K; Bergmann TK; Rodríguez-Antona C
    Clin Cancer Res; 2015 Jul; 21(13):3092-3. PubMed ID: 26133776
    [No Abstract]   [Full Text] [Related]  

  • 2. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response.
    Guo Q; Abraham JE; Caldas C; Earl HM; Pharoah PP;
    Clin Cancer Res; 2015 Jul; 21(13):3094. PubMed ID: 26133777
    [No Abstract]   [Full Text] [Related]  

  • 3. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
    Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
    Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.
    Azoulay D; Leibovici A; Sharoni R; Shaoul E; Gross B; Braester A; Goldberg H
    Breast Cancer Res Treat; 2015 Oct; 153(3):703-4. PubMed ID: 26272744
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and predictors of peripheral neuropathy after breast cancer treatment.
    Kamgar M; Greenwald MK; Assad H; Hastert TA; McLaughlin EM; Reding KW; Paskett ED; Bea JW; Shadyab AH; Neuhouser ML; Nassir R; Crane TE; Sreeram K; Simon MS
    Cancer Med; 2021 Oct; 10(19):6666-6676. PubMed ID: 34390205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
    Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
    Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term peripheral neuropathy symptoms in breast cancer survivors.
    Mustafa Ali M; Moeller M; Rybicki L; Moore HCF
    Breast Cancer Res Treat; 2017 Nov; 166(2):519-526. PubMed ID: 28791499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.
    Tsuyuki S; Senda N; Kanng Y; Yamaguchi A; Yoshibayashi H; Kikawa Y; Katakami N; Kato H; Hashimoto T; Okuno T; Yamauchi A; Inamoto T
    Breast Cancer Res Treat; 2016 Nov; 160(1):61-67. PubMed ID: 27620884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
    Fukada I; Ito Y; Kobayashi K; Shibayama T; Takahashi S; Horii R; Akiyama F; Iwase T; Ohno S
    PLoS One; 2017; 12(9):e0184322. PubMed ID: 28898275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced peripheral neuropathy: Current status and progress.
    Brewer JR; Morrison G; Dolan ME; Fleming GF
    Gynecol Oncol; 2016 Jan; 140(1):176-83. PubMed ID: 26556766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient.
    Hikino H; Kawashima M; Yamada T; Ozaki N
    Int J Clin Oncol; 2006 Aug; 11(4):332-5. PubMed ID: 16937310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine].
    Nagashima S; Kiba T; Ogawa Y; Mura T; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2015 May; 42(5):617-9. PubMed ID: 25981658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.
    Eckhoff L; Feddersen S; Knoop AS; Ewertz M; Bergmann TK
    Acta Oncol; 2015 Apr; 54(4):530-7. PubMed ID: 25383449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel-Letter.
    Clin Cancer Res; 2015 Sep; 21(18):4244. PubMed ID: 26374076
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer.
    Nurgalieva Z; Xia R; Liu CC; Burau K; Hardy D; Du XL
    Am J Ther; 2010; 17(2):148-58. PubMed ID: 19417586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.
    Eckhoff L; Knoop AS; Jensen MB; Ejlertsen B; Ewertz M
    Breast Cancer Res Treat; 2013 Nov; 142(1):109-18. PubMed ID: 24132874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Han SW; Jeon YK; Oh DY; Han W; Kim TY; Park IA; Noh DY; Bang YJ
    Oncology; 2012; 83(4):218-27. PubMed ID: 22906996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
    Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.